NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Elanco Animal Health Incorporated ELAN
10 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$4.7B
▲ 6.2% vs FY2024
EPS · FY25
$-0.47
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-3.7%
Net margin · FY25
-4.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 4.7B
Revenue, FY2025 · full 10-year series below
Revenue
Net income
The company lost 5 cents on every revenue dollar this year.
Per share
USD -0.47
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-3.7%
Return on equity, FY2025
ROE
Operating margin-4.8%
Net margin-4.9%
Return on assets-1.8%
Each USD of equity lost 4 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+7.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+2.2%
+7.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.50B
Shares outstanding, FY2025
Change, 5 years+5.3%
Change, 10 years—
The share count grew 5% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 13.4B
total assets, end of FY2025
Total assetsUSD 13.4B
EquityUSD 6.5B
CashUSD 545.0M
Gross debtUSD 3.8B
Net debtUSD 3.2B
Current ratio2.17×
Net debt stands at 49% of equity.
History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
4.7
4.4
4.4
4.4
4.8
3.3
3.1
3.1
2.9
2.9
Operating income $B
−0.2
0.5
−1.2
−0.1
−0.6
−0.7
0.1
0.1
−0.2
−0.0
EBITDA $B
0.5
1.1
−0.5
0.6
0.1
−0.2
0.4
0.4
0.1
0.2
Income tax $B
0.0
0.1
0.0
0.0
−0.1
−0.1
0.0
0.0
0.1
0.0
Net income $B
−0.2
0.3
−1.2
−0.1
−0.5
−0.6
0.1
0.1
−0.3
−0.0
EPS, diluted $
−0.47
0.68
−2.50
−0.16
−0.99
−1.30
0.18
0.28
−1.06
−0.16
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
−3.7
5.5
−18.2
−1.1
−6.1
−8.2
1.3
1.3
−4.2
−0.7
Shares out B
0.50
0.49
0.49
0.47
0.47
0.47
0.37
0.37
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
31 of 31
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed